Androgens in male contraception.
androgens
male hormonal contraception
sperm suppression
Journal
Best practice & research. Clinical endocrinology & metabolism
ISSN: 1878-1594
Titre abrégé: Best Pract Res Clin Endocrinol Metab
Pays: Netherlands
ID NLM: 101120682
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
pubmed:
8
3
2022
medline:
5
10
2022
entrez:
7
3
2022
Statut:
ppublish
Résumé
Rates of unplanned pregnancies are high globally, burdening women and families. Efforts to develop male contraceptive agents have been thwarted by unacceptable failure rates, side effects and a dearth of pharmaceutical industry involvement. Hormonal male contraception consists of exogenous androgens which exert negative feedback on the hypothalamic-pituitary-gonadal axis and suppress gonadotropin production. This in turn suppresses testicular testosterone production and sperm maturation. Addition of a progestin suppresses spermatogenesis more effectively in men. Contraceptive efficacy studies in couples have shown male hormonal methods are effective and reversible, but also may come with side effects related to sexual desire, acne and serum cholesterol and inconvenient methods of dosing and delivery. Recently, novel androgens as potential contraceptive agents are being evaluated in early clinical trials and look to overcome these drawbacks. Here we summarize landmark studies of prototype male hormonal contraceptives, showcasing recent advances and future prospects in this important area of public health.
Identifiants
pubmed: 35249804
pii: S1521-690X(22)00014-8
doi: 10.1016/j.beem.2022.101627
pii:
doi:
Substances chimiques
Androgens
0
Contraceptive Agents, Male
0
Gonadotropins
0
Progestins
0
Testosterone
3XMK78S47O
Cholesterol
97C5T2UQ7J
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
101627Subventions
Organisme : NICHD NIH HHS
ID : HHSN275201300025I
Pays : United States
Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest STP: One-time consultant for Clarus Therapeutics. AT: Nothing to disclose.